Alnylam Pharmaceuticals (ALNY) Stock Price vs Operating Income
Open the interactive overlay on autario.com.
Alnylam Pharmaceuticals reported Q3 2025 operating income of $368.0M, a significant swing from a $76.9M operating loss in Q3 2024. Over the same one-year period, the stock price rose from approximately $159.58 (April 2022 reference point in available data) to $285.38 as of June 2, 2026, reflecting a substantial increase in share value. Despite the dramatic improvement in profitability, the low correlation of 0.16 between operating income and stock price over the full 22-year window indicates the stock has moved largely independently of quarterly earnings trends. The company has remained unprofitable in most quarters from 2020 through early 2024, yet the stock more than tripled from $89.76 in January 2014 to $285.38 by mid-2026.
Operating Income was $368.0M as of 2025-09-30 (10-Q); the stock traded at $456.00. Not enough overlapping price and reporting history yet for a year-over-year comparison.
Latest close: 287.77 USD (2026-06-02).
Operating Income | recent SEC reports
| Report date | Operating Income | Period |
|---|
| 2025-09-30 | 368.0M USD | Q3 10-Q |
| 2025-06-30 | -16.2M USD | Q2 10-Q |
| 2024-09-30 | -76.9M USD | Q3 10-Q |
| 2024-06-30 | 48.6M USD | Q2 10-Q |
| 2024-03-31 | -43.4M USD | Q1 10-Q |
| 2023-09-30 | 213.9M USD | Q3 10-Q |
| 2023-06-30 | -229.8M USD | Q2 10-Q |
| 2023-03-31 | -149.8M USD | Q1 10-Q |
Sources: autario.com/data/stock-alny-alnylam-pharmaceuticals-daily-prices · autario.com/data/alnylam-pharmaceuticals-operating-income-sec-filings | data verified and hosted on autario.com.